Galderma Group AG (CHIX:GALDZ) Change In Receivables : CHF-186 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Change In Receivables?

Galderma Group AG's change in receivables for the quarter that ended in Dec. 2024 was CHF-5 Mil. It means Galderma Group AG's Accounts Receivable increased by CHF5 Mil from Jun. 2024 to Dec. 2024 .

Galderma Group AG's change in receivables for the fiscal year that ended in Dec. 2024 was CHF-185 Mil. It means Galderma Group AG's Accounts Receivable increased by CHF185 Mil from Dec. 2023 to Dec. 2024 .

Galderma Group AG's Accounts Receivable for the quarter that ended in Dec. 2024 was CHF672 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Galderma Group AG's Days Sales Outstanding for the six months ended in Dec. 2024 was 61.87.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Galderma Group AG's liquidation value for the six months ended in Dec. 2024 was CHF-3,212 Mil.

Galderma Group AG Change In Receivables Historical Data

The historical data trend for Galderma Group AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Change In Receivables Chart

Galderma Group AG Annual Data

Trend

Dec23

Dec24

Change In Receivables

40.65

-185.45

Galderma Group AG Semi-Annual Data
	Jun23	Dec23	Jun24	Dec24
Change In Receivables	-60.33	98.59	-180.55	-5.35

Galderma Group AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-186 Mil.

Galderma Group AG (CHIX:GALDz) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Galderma Group AG's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	672.266	/	1982.918	*	91
=	61.87

2. In Ben Graham's calculation of liquidation value, Galderma Group AG's accounts receivable are only considered to be worth 75% of book value:

Galderma Group AG's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	407.461	-	4303.753	+	0.75 * 672.266	+	0.5 * 359.315
=	-3,212

Galderma Group AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (CHIX:GALDz) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

GALDY:USA GDERF:USA PY30:Germany GALD:Switzerland

Address

Zahlerweg 10, Zug, CHE, 6300

Website

https://www.galderma.com

Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines